- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04944550
New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract. (CICLOP)
Development of New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.
Upper Urinary Tract Urothelial Carcinomas are rare, aggressive tumors, accounting for 5 to 10% of all urothelial tumors. These include tumors which develop in the renal cavities (renal pelvis, calices) and ureteral tumors. Nephro-ureterectomy is the standard treatment but 80% of patients will have a relapse within 2 years. Only one trial has (Birtle et al. 2020), has shown the interest of postoperative chemotherapy. Neoadjuvant systemic treatment seems particularly interesting for a population which is going to undergo a nephronic loss and therefore reduction in kidney function which is likely to make patients ineligible for cisplatin. In favor of additional immunotherapy, it has been described that upper excretory tract tumors have a high immunogenic potential with a high rate of microsatellite instability.
From surgical samples of patient tumors obtained after nephroureterectomy or biopsy material collected before treatment, we are going to generate patient-derived cell lines and xenograft models in the mouse. A recent publication has demonstrated the feasibility of this approach by specifying that the capture rate of tumor cells is 50% for patient-derived xenografts and 25% for patient-derived cells (Coleman et al. 2020). As tumors harvested from biopsies do not grow in patient-derived xenografts,we plan to graft the biopsies onto chorioallantoic chicken embryo membranes, a model which has never been used for this indication and which is one of the original features of our approach. These three concomitant approaches will allow us to increase our chances of obtaining stable upper urinary tract urothelial carcinoma lines to be used for the screening and identification of new treatments or new combinations of molecules that would benefit patients with upper urinary tract urothelial carcinomas, knowing that very few studies dedicated to this type of cancer have been conducted or published due to the rarity of the disease and the lack of existing models published on the subject of these particular tumors.
.
Studienübersicht
Status
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Nadine HOUEDE, Pr.
- Telefonnummer: +33 4.66.68.33.01
- E-Mail: nadine.houede@chu-nimes.fr
Studieren Sie die Kontaktsicherung
- Name: Anissa MEGZARI, Mme.
- Telefonnummer: 04.66.68.42.36
- E-Mail: drc@chu-nimes.fr
Studienorte
-
-
Gard
-
Nîmes, Gard, Frankreich, 30029
- Rekrutierung
- Centre Hospitalier Universitaire de Nîmes
-
Kontakt:
- Anissa MEZGARI
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Patients treated consecutively at the Urology Andrology Department of Nîmes University Hospital for high grade carcinoma of the pelvis or renal ureter with an indication for total nephroureterectomy decided during a multidisciplinary meeting.
- Patient with a diagnosis of high-grade urothelial carcinoma of the pelvis or renal ureter confirmed by histology (biopsy, biopsy of the ureteroscopic) or by cytology with the presence of :
- High-grade disease on ureteroscopic biopsy OR ;
- High grade disease on urinary cytology AND infiltrating appearance of the renal pelvic wall / ureter on the scanner (the presence of hydronephrosis will be considered as pervasive by definition) with a negative cytoscopy.
Exclusion Criteria:
- Any patient who has undergone previous systemic treatment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Histological characteristics of patient-derived xenograft models after staining.
Zeitfenster: 1-6 months after harvesting
|
Microscopic observation of cells after staining with hematoxylin and eosin
|
1-6 months after harvesting
|
Study of genomes of tumor specimens
Zeitfenster: 1-6 months after harvesting
|
Exome sequencing of DNA cells isolated from original patient tumor specimens.
|
1-6 months after harvesting
|
Alterations in the genomes of patient-derived xenograft tumor models
Zeitfenster: 1-6 months after harvesting
|
Exome sequencing of DNA cells isolated from patient-derived xenograft tumor models.
|
1-6 months after harvesting
|
Alterations in the genomes of patient-derived cell line models
Zeitfenster: 1-6 months after harvesting
|
Exome sequencing of DNA cells isolated from patient-derived cell line models.
|
1-6 months after harvesting
|
Study of the transcriptome of patient tumor specimens.
Zeitfenster: 1-6 months after harvesting
|
RNA-sequencing of cells isolated from patient tumor specimens.
|
1-6 months after harvesting
|
Transcriptome of the patient-derived xenograft tumor models.
Zeitfenster: 1-6 months after harvesting
|
RNA-sequencing of cells isolated from patient-derived xenograft tumor models.
|
1-6 months after harvesting
|
Transcriptome of the patient-derived cell line models.
Zeitfenster: 1-6 months after harvesting
|
RNA-sequencing of cells isolated from patient-derived cell line models.
|
1-6 months after harvesting
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Sensitivity to Cisplatin: patient-derived cell line models
Zeitfenster: 6-8 months after harvesting
|
The MIC 50 test (Minimum Inhibitory Concentration required for cell growth to be inhibited by 50%) will be used in vitro to test the tumor cells' response to Cisplatin.
|
6-8 months after harvesting
|
Sensitivity to Carboplatin: patient-derived cell line models
Zeitfenster: 6-8 months after harvesting
|
The MIC 50 test (Minimum Inhibitory Concentration required for cell growth to be inhibited by 50%) will be used in vitro to test the tumor cells' response to Carboplatin.
|
6-8 months after harvesting
|
Sensitivity to Oxaliplatin: patient-derived cell line models
Zeitfenster: 6-8 months after harvesting
|
The MIC 50 test (Minimum Inhibitory Concentration required for cell growth to be inhibited by 50%) will be used in vitro to test the tumor cells' response to Oxaliplatin.
|
6-8 months after harvesting
|
Sensitivity to Gemcitabin: patient-derived cell line models
Zeitfenster: 6-8 months after harvesting
|
The MIC 50 test (Minimum Inhibitory Concentration required for cell growth to be inhibited by 50%) will be used in vitro to test the tumor cells' response to Gemcitabin.
|
6-8 months after harvesting
|
Tumor size in non-treated patient-derived xenograft models
Zeitfenster: 1-6 months after harvesting
|
The volume of tumors will be measured in mm3.
|
1-6 months after harvesting
|
Sensitivity to Cisplatin: tumor size in treated patient-derived xenograft models
Zeitfenster: 6-8 months after harvesting
|
To test the tumor cells' response to Cisplatin in xenograft models, the volume of tumors will be measured in mm3 and compared with the volume of tumors in the non-treated control group.
|
6-8 months after harvesting
|
Sensitivity to Cisplatin: tumor growth rate in patient-derived xenograft models
Zeitfenster: 6-8 months after harvesting
|
To test the tumor cells' response to Cisplatin in xenograft models, the Tumor Growth Inhibition index, which is defined as (1 - (mean volume of treated tumors)/(mean volume of control tumors)) × 100% will be used.
|
6-8 months after harvesting
|
Sensitivity to Carboplatin: tumor size in treated patient-derived xenograft models
Zeitfenster: 6-8 months after harvesting
|
To test the tumor cells' response to Carboplatin in xenograft models, the volume of tumors will be measured in mm3 and compared with the volume of tumors in the non-treated control group.
|
6-8 months after harvesting
|
Sensitivity to Carboplatin: tumor growth rate in treated patient-derived xenograft models
Zeitfenster: 6-8 months after harvesting
|
To test the tumor cells' response to Carboplatin in xenograft models, the Tumor Growth Inhibition index, which is defined as (1 - (mean volume of treated tumors)/(mean volume of control tumors)) × 100% will be used.
|
6-8 months after harvesting
|
Sensitivity to Oxiplatin: tumor size in treated patient-derived xenograft models
Zeitfenster: 6-8 months after harvesting
|
To test the tumor cells' response to Oxiplatin in xenograft models, the volume of tumors will be measured in mm and compared with the volume of tumors in the non-treated control group.
|
6-8 months after harvesting
|
Sensitivity to Oxiplatin: tumor growth rate in treated patient-derived xenograft models
Zeitfenster: 6-8 months after harvesting
|
To test the tumor cells' response to Oxiplatin in xenograft models, the Tumor Growth Inhibition index, which is defined as (1 - (mean volume of treated tumors)/(mean volume of control tumors)) × 100% will be used.
|
6-8 months after harvesting
|
Sensitivity to Gemcitabine: tumor size in treated patient-derived xenograft models
Zeitfenster: 6-8 months after harvesting
|
To test the tumor cells' response to Gemcitabine in xenograft models, the tumor volume will be measured in mm3 and compared with the volume of tumors in the non-treated control group.
|
6-8 months after harvesting
|
Sensitivity to Gemcitabin: tumor growth rate in treated patient-derived xenograft models
Zeitfenster: 6-8 months after harvesting
|
To test the tumor cells' response to Gemcitabin in xenograft models, the Tumor Growth Inhibition index, which is defined as (1 - (mean volume of treated tumors)/(mean volume of control tumors)) × 100% will be used.
|
6-8 months after harvesting
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Patients' gender
Zeitfenster: Day 0
|
The sex of patients will be recorded at the inclusion as Male/Female/Transgender
|
Day 0
|
Patients' age
Zeitfenster: Day 0
|
The age of patients will be recorded at the inclusion in years
|
Day 0
|
Primitive tumor site
Zeitfenster: Day 0
|
The site of the patient's primitive tumor will be recorded at the inclusion
|
Day 0
|
Infiltrative tumor
Zeitfenster: Day 0
|
The tumor will be noted as infiltrative or not (YES/NO) at the inclusion.
|
Day 0
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Nadine HOUEDE, Pr., Chu de Nimes
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NIMAO/2020-2/NH01
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Tumor
-
Aadi Bioscience, Inc.RekrutierungFortgeschrittener solider Tumor | Tumor | Tumor, solideVereinigte Staaten
-
Baodong QinRekrutierungRefraktärer Tumor | Seltener TumorChina
-
RemeGen Co., Ltd.AbgeschlossenMetastasierter solider Tumor | Lokal fortgeschrittener solider Tumor | Nicht resezierbarer solider TumorAustralien
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRekrutierungSolider Tumor, Erwachsener | Refraktärer TumorVereinigte Staaten
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnbekanntFortgeschrittener solider Tumor oder hämatologischer TumorChina
-
Second Affiliated Hospital of Soochow UniversitySciClone PharmaceuticalsRekrutierungFortgeschrittener solider Tumor | Refraktärer TumorChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RekrutierungEine Studie zur Bewertung der Verträglichkeit, Wirksamkeit und Pharmakokinetik von TQB3454-TablettenFortgeschrittener solider Tumor oder hämatologischer TumorChina
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRekrutierungFortgeschrittener solider Tumor | Metastasierter solider TumorVereinigte Staaten
-
PharmaEngineNoch keine RekrutierungFortgeschrittener solider Tumor | Metastasierter solider Tumor
-
Daiichi SankyoRekrutierungFortgeschrittener solider Tumor | Metastasierter solider TumorVereinigte Staaten, Japan